Objective: Many stroke patients show remarkable recovery of language after initial severe impairment, but it is difficult to predict which patients will show good recovery. We aimed to identify patient and lesion characteristics that together predict the best naming outcome in 4 studies. Methods: We report 2 longitudinal studies that identified 2 variables at onset that were strongly associated with good recovery of naming (the most common residual deficit in aphasia) in the first 6 months after stroke: damage to left posterior superior temporal gyrus (pSTG) and/or superior longitudinal fasciculus/arcuate fasciculus (SLF/AF), and selective serotonin reuptake inhibitor (SSRI) use. We then tested these variables in 2 independent cohorts of chronic left hemisphere stroke patients, using chi-square tests and multivariate logistic regression for dichotomous outcomes and t tests for continuous outcomes. Results: Lesion load in left pSTG and SLF/AF was associated with poorer naming outcome. Preservation of these areas and use of SSRIs were associated with naming recovery, independent of lesion volume, time since stroke, and depression. Patients with damage to these critical areas showed better naming outcome if they took SSRIs for 3 months after stroke. Those with preservation of these critical areas achieved good recovery of naming regardless of SSRI use. Interpretation: Lesion load in left pSTG and SLF/AF at onset predicts later naming performance. Although based on a small number of patients, our preliminary results suggest outcome might be modulated by SSRIs, but these associations need to be confirmed in a larger randomized controlled trial. ANN NEUROL 2018;83:612-622 A phasia is among the most common and disabling consequences of stroke.
possible to predict which individuals will show substantial recovery of language and which individuals will show little recovery or even decline.
Studies of aphasia recovery have evaluated people at different times poststroke to identify variables associated with good versus poor recovery. [2] [3] [4] [5] [6] One large crosssectional study showed that aphasia severity was associated with stroke volume, time postonset, and percentage of damage to 35 brain regions. 2 Three studies have shown a strong association between lesion load in the arcuate fasciculus (AF; along with the integrity of right hemisphere white matter tracts 5 and outcome of naming and speech fluency in poststroke aphasia. [4] [5] [6] One longitudinal study of 21 aphasic individuals showed that age, initial severity, and the pattern of activation on functional imaging at baseline were associated with degree of impairment at 6 months. 7 Other longitudinal aphasia studies have shown that lesion volume, 2, 8 initial severity, [9] [10] [11] [12] and education 11 influence recovery. However, variables associated with outcome have not been prospectively evaluated in an independent population to determine whether the same variables predict later recovery.
To our knowledge, no previous study has evaluated the independent contributions of lesion site and medications. There are several mechanisms by which selective serotonin reuptake inhibitors (SSRIs), which elevate synaptic serotonin, might enhance recovery by augmenting synaptic plasticity. 13, 14 SSRIs increase brain-derived neurotrophic factor, 15 which may be a critical modulator of recovery. 16 These mechanisms might account for the positive effect of an SSRI on human motor recovery 17 and cognitive performance. 18 Other small studies have reported positive effects of antidepressants on aphasia 3, [19] [20] [21] (but see Laska et al). 22 Here, we report novel evidence to improve prediction of aphasia recovery. We report 2 longitudinal studies in which we identify variables associated with the degree of language recovery over the first 6 months. We then use these data to predict which individuals are likely to have made the best recovery of language later after stroke, in 2 independent samples of chronic stroke patients who initially had aphasia. Based on our initial longitudinal studies, we hypothesized that individuals without lesions involving 2 critical areas were more likely to show recovery of naming than those with these lesions. The critical areas were: left superior temporal gyrus (STG) posterior to the pole (areas STG and posterior STG [pSTG] on the Johns Hopkins UniversityMontreal Neurological Institute [JHU-MNI] atlas, cmrm.med.jhmi.edu) and superior longitudinal fasciculus (SLF in the JHU-MNI atlas, equivalent to the AF in the Catani atlas, https://www.natbrainlab.co.uk/atlas-maps).
Results confirmed the influence of lesion load in left AF on aphasia outcome, [4] [5] [6] and revealed an additional influence of lesion load in left pSTG. We also hypothesized that, among aphasic individuals whose lesions involved left pSTG or SLF/AF, recovery would be greatest in those who took an SSRI daily for at least 3 months after stroke. We focused on naming because impaired naming is the most common and important residual language deficit in poststroke aphasia. This deficit impedes effective and efficient communication in daily interactions.
Patients and Methods
The protocol for this study received prior approval by the institutional review boards of Johns Hopkins, University of South Carolina, and Medical University of South Carolina. Informed consent was obtained from each participant or their legally authorized representative (for individuals with impaired language comprehension). We conducted 4 independent, complementary studies, summarized in Table 1 .
Participants
LONGITUDINAL STUDIES. Participants were enrolled at Johns Hopkins Hospital in the first 48 hours after left hemisphere ischemic stroke. Exclusion criteria included: impaired level of consciousness or ongoing sedation, lack of premorbid competence in English, previous neurological disease affecting the brain, and contraindication for magnetic resonance imaging (MRI; eg, implanted ferrous metal, claustrophobia). For these studies, we included only those who initially had aphasia as scored on the National Institutes of Health Stroke Scale. 23 In our first longitudinal study of 19 patients, the mean age was 54.8 6 13.2 (standard deviation) years; 36.8% were female ( Table 2 ). The second longitudinal study began when we started recording antidepressant use. We enrolled 30 aphasic patients; the mean age was 57.5 6 12.2 years, and 29.0% were female. Both studies were a consecutive series of patients who met all inclusion criteria and returned for follow-up testing at 6 months. They represent subsets of 207 patients who completed the language testing and had MRI at the acute time point, of whom 128 had aphasia at onset. The most frequent reason for failure to follow up was that the participant could not be reached. At least 2 had died, and at least 3 had new strokes in the 6-month interval.
CROSS-SECTIONAL STUDIES. Participants in our crosssectional studies were assessed to validate the variables associated with best recovery in 2 independent groups enrolled at separate centers. These studies involved retrospective analyses of prospectively collected data. Participants in the first crosssectional group (n 5 159) were enrolled at the University of South Carolina or Medical University of South Carolina at least 6 months after left hemisphere ischemic stroke. Mean months poststroke at time of testing was 34 6 40 (range 5 6-276). The mean age was 59.8 6 11 years; 37.7% were female. Mean lesion volume was 118.1 6 97ml, and mean aphasia quotient (AQ; measured using the Western Aphasia Battery-Revised [WAB-R] 24 ) was 63. 3 6 28.9 . In this cohort, we tested only the first hypothesis, that is, that lesions in left pSTG and/or SLF/AF are associated with poorer recovery of naming in chronic stroke compared to individuals without damage to these areas, because medication information was not available.
Participants in the second cross-sectional group included 43 patients recovering from left hemisphere ischemic stroke who were enrolled at Johns Hopkins Hospital at a mean of 39 6 36 months poststroke. The mean age was 56.1 6 15.1 years; 51.1% were female. Mean lesion volume was 188.8 6 200.7ml, and mean AQ was 74.5 6 30.9. For this group, both imaging and medication use were available. Therefore, in this group, we evaluated our second hypothesis, that among individuals with damage to left pSTG and/or SLF/AF, those who continuously take SSRIs during the first 3 months show better recovery than nonusers of SSRIs.
Each of these study populations was a convenience sample of individuals who met inclusion and exclusion criteria and had the available data. The populations were similar in aphasia severity [24] [25] [26] [27] with a wide range of scores in aphasic individuals, and because it is the most commonly reported residual deficit. In the first longitudinal study, we evaluated performance on the Boston Naming Test (BNT) short form (BNTsf; 30 items) 26 within 48 hours and 6 months (range 5 5-7 months) after stroke onset.
In the second longitudinal study, we evaluated performance on the BNT 26 and also evaluated naming in the context of picture description at the same 3 time points. For the latter, participants were asked to describe everything they could see in the Cookie Theft picture that is part of the Boston Diagnostic Aphasia Examination, 25 and more recently has been incorporated in the National Institutes of Health Stroke Scale used worldwide. 23 Picture descriptions were scored for the number of Cookie Theft Correct Content Units (items mentioned by 31 healthy controls in describing the same picture). This measure correlates with aphasia severity measured by more extensive batteries, 27 and correlates with performance on the BNTsf in our first longitudinal cohort (r 2 5 0.72, p 5 0.0005). Two independent speech language pathologists scoring Cookie Theft Correct Content Units achieved point-to-point agreement of 96.7%.
CROSS-SECTIONAL STUDIES OF CHRONIC APHASIA. ParParticipants in both cross-sectional groups described above were administered the WAB-R. Our primary outcome variable of interest was naming, tested with the object naming subtest. Accuracy is measured by percentage correct of 60 items. This score was highly correlated with the BNT score in participants at the University of South Carolina or Medical University of South Carolina who had both tests at the same time point (r 2 5 0.88). However, not all participants had been administered the BNT (n 5 118/159). We also evaluated naming outcome using the WAB-R word fluency subtest (naming items rapidly in a given category) and overall language outcome using the WAB-R AQ (a summary score based on all auditory-verbal language subtests).
Medication Use
We recorded use of antidepressants (which included SSRIs, tricyclic antidepressants, venlafaxine, duloxetine, and bupropion) continuously for the first 3 months after stroke, by interview of participants, confirmed with information from the individual's pharmacy (available through medical records).
Depression Assessment
In both the longitudinal study and the cross-sectional study that evaluated the effect of antidepressants, we also evaluated for depression using the Patient Health Questionnaire-9 (PHQ-9). 28 In a study of 200 stroke patients within 1 month of onset, a score of 10 on the PHQ-9 had 91% sensitivity and 87% specificity for depression, compared to a structured psychiatric interview. 29 
Imaging and Statistical Analyses
For the 2 studies that used parcel-based lesion symptom mapping (PSLM) to identify (longitudinally) or validate (cross-sectionally) areas associated with recovery, participants underwent high-resolution (voxel size 5 1mm
3 ) structural MRI that included T1-MRI and T2-MRI. For acute patients, MRI also included diffusion-weighted imaging (DWI) and apparent diffusion coefficient maps to identify acutely infarcted areas. The stroke lesion was demarcated on DWI trace image (for acute patients) or T2-weighted images (for chronic patients) by a neurologist highly experienced in lesion studies or by a study team member supervised by a neurologist. For acute patients, the normalization transforms were computed for the DWI B 5 0 image (which does not yet show stroke-related abnormalities) to a template based on age-matched controls. 30 The normalization parameters were then applied to the DWI tracebased lesion. A different approach was used for chronic patients, as lesion-based abnormalities are seen in all modalities. For chronic patients, the lesion was drawn on a high-resolution T2 image that was coregistered to the T1 image. The resliced lesion maps were smoothed with a 3mm full-width at halfmaximum Gaussian kernel to remove jagged edges associated with manual drawing. To align the T1 image to standard space, we used enantiomorphic normalization 31 as implemented in the Clinical Toolbox 30 for SPM12. First, a mirrored image of the T1 image (reflected around the midline) was coregistered to the native T1 image. Then, we created a chimeric image based on the native T1 image with the lesioned tissue replaced by tissue from the mirrored image (using the smoothed lesion map to modulate this blending, feathering the lesion edge). SPM12's unified segmentation normalization 32 was used to warp this chimeric image to standard space, with the resulting spatial transform applied to the actual T1 image as well as the lesion map. The normalized lesion map was then binarized, using a 50% probability threshold. PSLM analyses were completed to identify localized brain damage associated with naming outcome. Each analysis related naming performance to proportional damage to regions included in the JHU-MNI atlas. 33 The threshold level of significance selected was 0.05. In the first longitudinal study from the acute stage of stroke (with 19 patients), associations between lesioned brain regions and naming deficits were computed using a general linear model (least squares linear regression) and corrected for multiple comparisons using Bonferroni correction. As parcels that are infrequently damaged will have low statistical power while increasing the number of comparisons, only parcels where at least 8 participants had any damage were included in the analyses. To control for lesion volume, it was regressed out of behavioral scores. In the cross-sectional study of 159 participants, multiple comparisons were corrected using permutation thresholding, with 4,000 permutations; Freedman-Lane testing was applied to correct for lesion volume (as a nuisance regressor within permutation thresholding). Only parcels where at least 10 participants had any damage were included in the analyses. Note that inclusion of lesion volume and excluding rarely injured regions have been shown to attenuate some of the spatial biases inherent to lesion-symptom mapping. 34 The lesion-symptom analysis for both acute and chronic patients relied on routines integrated into the NiiStat toolbox for MATLAB (http://www.nitrc.org/projects/niistat). In addition to the PSLM to determine the areas where damage was associated with poorer outcome of naming in a longitudinal study and a cross-sectional study of chronic stroke, described above, we evaluated the influence of using SSRIs continuously for the first 3 months, lesion volume, and lesion site in both a longitudinal study and a cross-sectional study. We also recorded use of other antidepressants, but did not evaluate their influence, because other antidepressants were used by only 8 (duloxetine, n 5 5; buproprion, n 5 3) of 30 patients in the longitudinal study, and only 4 (duloxetine, n 5 2; buproprion, n 5 2) of 43 patients in the cross-sectional study. In the longitudinal study, we tested the hypothesis from earlier studies 9, 35 that stroke patients typically achieve 70% of their maximal potential recovery, when maximum potential recovery is defined as the maximum score minus the initial score. We identified Pearson correlations (and absolute differences) between expected recovery (70% of maximal recovery) and observed recovery. For remaining analyses, naming improvement was measured by change in object naming divided by the initial score on object naming. We then tested the predictions based on this longitudinal study in a cross-sectional study of chronic stroke in which medication use from the acute stage was available. We evaluated the independent contributions of antidepressant use, lesion variables, and time since onset of stroke with logistic regression. We also evaluated associations between dichotomized naming outcomes and each antidepressant medication with Pearson chisquare tests. Behavioral differences between participants who took each antidepressant versus those who did not take that antidepressant were analyzed in naming recovery using Student t tests. These statistical analyses were carried out using Stata version 12.4.
Results
Longitudinal Study: Johns Hopkins (n 5 19; PSLM) In the first longitudinal study from the acute period (<48 hours) through month 6, the only regions where percentage damage (lesion load) was associated with naming outcome at month 6, after controlling for lesion volume and multiple comparisons, were left pSTG and SLF/AF (Fig. 1) . SLF/AF here refers to a bundle of white matter tracts in the dorsolateral corona radiata that includes connections between the frontal, parietal, temporal, and occipital lobes. It includes all 3 subcomponents of the AF described by Markris et al. 36 There was a significant correlation between expected recovery (70% of maximal recovery) and observed recovery (r 2 5 0.50, p 5 0.001). However, deviation from expected recovery varied from 234% to 30% of total score (see Table 1 , Fig 2) ; 42% deviated from expected recovery by >10% of the maximum score.
Longitudinal Study: Johns Hopkins (n 5 30; SSRI Use) In this study, we identified the effects of antidepressants and lesion variables on change in BNT and change in Cookie Theft Correct Content Units. We found that 71% showed improvement on the BNT, 5% showed no change at all, and 21% showed decline. Likewise, 69% showed improvement in Cookie Theft Correct Content Units, 9% showed no change, and 22% showed decline. That is, roughly the lowest quartile of change on language tests were negative values (decline); the next lowest was little or no change. Good improvement was defined as the upper 50th percentile. In the entire cohort, 11 participants (37%) used SSRIs, 5 (17%) used duloxetine, 3 (10%) used bupropion, and only 1 individual each used tricyclic antidepressants or venlafaxine. Of the SSRI users, 9 took fluoxetine, 1 took escitalopram, and 1 took sertraline. No other antidepressants were prescribed in this cohort. Continuous SSRI use in the first 3 months (compared to SSRI nonuse) was associated with greater frequency of obtaining good improvement in both the BNT score (88% vs 33%, v There were no differences between SSRI users and nonusers in age, education, lesion volume, initial severity (BNT score), or depression (PHQ-9 scores at outcome). None of these variables alone or together predicted SSRI use (Table 3) . In multivariate analysis, SSRI use, age, and education were associated with improvement in BNT Cross-Sectional Study: South Carolina (n 5 159) Two cross-sectional studies were carried out to test predictors of recovery identified in the longitudinal studies in independent populations. The first examined chronic stroke patients from the University of South Carolina or Medical University of South Carolina; we tested the hypothesis derived from the first longitudinal study, that damage to left pSTG or SLF/AF is associated with worse naming outcome. Using PSLM, the only lesion locations that predicted poor naming accuracy were left STG (between STG pole and pSTG; r 5 20.63), pSTG (r 5 20.53), and SLF/AF (r 5 20.65), all of which were significant associations at the level of p < 0.001, which suggests that these regions need to be intact for patients to experience good recovery of naming abilities (see Fig  3 for results in left panel, and the demarcations of these areas in the JHU-MNI atlas). Damage to the postcentral gyrus, anterior cingulate gyrus, and thalamus had the opposite effect, as patients with damage to those regions tended to name more items correctly compared to those participants who had damage elsewhere.
Cross-Sectional Study: Johns Hopkins (n 5 43)
In this study, we tested the hypothesis derived from the second longitudinal study (Johns Hopkins, n 5 30), that preservation of left pSTG and/or SLF/AF and SSRI use are associated with better naming outcome.
EFFECT OF LESION SITE. We confirmed that damage to left pSTG and/or SLF/AF was associated with lower chance of achieving the highest quartile of naming (6% vs 92%, v multiple comparisons. However, damage to pSTG and/or SLF/AF was not significantly associated with lower chance of achieving the highest quartile of WAB AQ (0% vs 83%, not significant [ns]) or highest quartile word fluency (17% vs 57%, ns) after correction. There was no difference in SSRI use between participants with and without left pSTG/SLF lesions (40% vs 35%, ns). In multivariate analysis, damage to left pSTG/SLF was Figure 4 .
Discussion
Although we confirmed previous findings that degree of recovery of naming is proportional to initial severity, the relationship was not as strong as reported in previous studies (particularly for motor recovery). Initial severity accounted for only 50% of the variance in recovery. Our data indicate that recovery of naming in poststroke aphasia is negatively influenced by lesion load in left pSTG and/or SLF/AF, and positively influenced by SSRI use in participants with lesions to these areas. We did not have images of initially aphasic man who achieved the highest quartile of recovery of naming (98.3% correct) after taking a selective serotonin reuptake inhibitor (SSRI) continuously for 3 months after stroke. Lower panel: FLAIR images of an initially aphasic man of the same age who failed to achieve the highest quartile of recovery of object naming at the same time point after stroke. He did not take an SSRI (or any antidepressant) after the stroke, and was not depressed.
sufficient numbers to evaluate the influence of other antidepressants. The effects could not be explained by the effects of lesion volume, depression, or initial severity, as we controlled for these variables. Although, as expected, there was a significant correlation between the degree of improvement and the degree of possible improvement, the change in naming divided by the initial score was influenced by SSRI use and damage to left pSTG and/or SLF/AF. The negative effect of left pSTG and/or SLF/AF damage on naming recovery is consistent with other studies indicating that these areas are critical to naming. Three studies have demonstrated that naming outcome depends on lesion load in the AF. [4] [5] [6] Damage to various parts of SLF/AF was also associated with poorer recovery of various aspects of language in a previous longitudinal study. 11 Our results confirm the critical role of left SLF/ AF and extend those findings by showing that lesion load in left pSTG is also critical to naming outcome. Three other studies showed dysfunction of left pSTG was associated with impairments in naming in stroke [38] [39] [40] ; another showed that production of semantic errors in naming was associated with dysfunction in left pSTG or damage to left posterior inferior temporal cortex. 41 However, another study found that other areas of infarction (left middle and inferior temporal gyrus anterior to the fusiform, as well as left STG posterior to STG pole) are associated with production of semantic errors in chronic stroke. 42 Differences between that study and our study include that we did not evaluate lesions associated with different types of naming errors and that we used different tests of naming. The main difference between the naming test used in the earlier study (the Philadelphia Naming Test [PNT] ) and those in the current study is that feedback is provided in the PNT. Furthermore, the 2 studies used different lesion-symptom mapping approaches. Our results reveal the influence of lesion load in left pSTG and SLF/AF on naming outcome, but do not rule out the influence of damage to other areas of language cortex, such as left posterior inferior frontal gyrus (pIFG), anterior temporal lobe (ATL), fusiform gyrus, or angular gyrus, where lesions cause naming deficits acutely. 38 Other areas may not have been found to have an independent influence on naming outcome because of inadequate power to detect their influence. Alternatively, it is possible that other areas of the brain can assume the functions of areas such as pIFG and ATL more readily than the functions of pSTG and SLF/AF. Larger longitudinal studies are needed to reveal the role of these other areas in naming outcome.
Our results regarding SSRIs, although preliminary, are consistent with findings of a positive effect of SSRIs in the first 3 months after stroke on motor recovery 17 and cognitive function, 18 independently of depression.
Results are also consistent with a previous crossover trial of SSRI use in 10 aphasic patients, which showed greater gains in naming in the SSRI condition, independently of the effects on depression. 43 Many patients are now prescribed SSRIs after acute ischemic stroke, irrespective of depression, because of the results of this randomized controlled trial, which indicated that SSRI is associated with better motor recovery. Nevertheless, there is high rate of poststroke depression, ranging from 30 to 60%, 44, 45 and poststroke depression can be significantly reduced with pharmacotherapy. 46 There may be several positive effects of SSRIs after stroke; the effects on mood (as assessed by this screening test) and language recovery appear to be relatively independent. 17, 47 Limitations of our research include that we did not evaluate the effects of SSRIs at different time periods after stroke or the influence of duration, dose, or type of SSRI. We also did not compare SSRIs to other antidepressants, because the number of participants taking various other antidepressants was low. Another limitation is that we relied on convenience samples of patients who met inclusion and exclusion criteria and had the available data (who prospectively enrolled in larger studies of aphasia recovery). Finally, our longitudinal studies were relatively small. Larger prospective studies are needed to determine the extent to which damage to left pSTG and/ or SLF/AF can prospectively predict recovery by a particular time point after stroke. A multicenter, randomized clinical trial is needed to determine whether SSRI use in the first 3 months after stroke or later is associated with better aphasia recovery, compared to placebo.
Despite its limitations, our results provide new information that will be useful in predicting at onset an individual's potential for good recovery from poststroke aphasia based on the location of damage.
